Home/Filings/4/0001439222-25-000093
4//SEC Filing

Goff Brian 4

Accession 0001439222-25-000093

CIK 0001439222other

Filed

Aug 11, 8:00 PM ET

Accepted

Aug 12, 4:24 PM ET

Size

8.9 KB

Accession

0001439222-25-000093

Insider Transaction Report

Form 4
Period: 2025-08-08
Goff Brian
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Restricted stock units

    2025-08-0822,6910 total
    Common stock (22,691 underlying)
  • Exercise/Conversion

    Common stock

    2025-08-08+22,691134,613 total
  • Sale

    Common stock

    2025-08-08$36.67/sh11,085$406,487123,528 total
Footnotes (3)
  • [F1]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated August 8, 2022.
  • [F2]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
  • [F3]The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.

Issuer

AGIOS PHARMACEUTICALS, INC.

CIK 0001439222

Entity typeother

Related Parties

1
  • filerCIK 0001546216

Filing Metadata

Form type
4
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 4:24 PM ET
Size
8.9 KB